Biologica Technologies exhibits latest foot and ankle arthrodesis data for ProteiOS® at The Midwest Podiatry Conference
10 Apr, 2019, 10:43 ET
CARLSBAD, Calif., April 10, 2019 /PRNewswire/ -- Biologica Technologies, LLC (the "Company" or "Biologica") announced today that they will be showcasing their latest clinical data for ProteiOS growth factor at this week's Midwest Podiatry Conference held in Chicago, IL.
ProteiOS is a unique, first of its kind allogeneic-derived growth factor that offers a number of distinct advantages over current products for foot & ankle arthrodesis. Other growth factor products used in foot & ankle fusion are comprised of one sole growth factor, whereas ProteiOS provides a full array of osteoinductive, angiogenic, chemotactic, and mitogenic growth factors. ProteiOS for foot and ankle fusion was launched via a targeted release in Q1 of 2018 and is now available across the USA.
Dr. Brian J. Burgess, staff physician at Hinsdale Orthopaedics and Department of Orthopedics Clinical Assistant Professor at Loyola University, commented, "I have found ProteiOS to be both predictable and safe in improving outcomes in my fusion patient population." He also added, "It provides reproducible results in a safe and economical way."
"We have been excited about the reception of ProteiOS with foot and ankle surgeons," stated Vice President of Sales and Marketing, Scott Cadotte. "Just as we have seen with spine surgeons, the early clinical results combined with the ability for a surgeon to use their preferred scaffold has been received very positively."
ProteiOS growth factor is a unique, first of its kind allogeneic-derived growth factor that provides a number of distinct advantages over current osteobiologic offerings. It possesses an array of osteoinductive, angiogenic, chemotactic and mitogenic growth factors and contains the highest amount of non-recombinant growth factors in the market today. In addition, ProteiOS allows surgeons the ability to use their preferred osteoconductive scaffold of choice and provides cost savings over rhBMP-2, rhPDGF-BB and allogeneic stem cells.
About Biologica Technologies
Founded in 2015, Biologica Technologies is a company focused on providing clinically relevant biologic solutions across multiple medical specialties. Biologica has developed innovative and ground breaking methods to access the naturally occurring growth factors found within allograft tissue, with ProteiOS growth factor being their first introduction into the orthopaedic and neurosurgery markets. The company is privately-held and headquartered in Carlsbad, CA.
SOURCE Biologica Technologies, LLC
Share this article